Y-mabs Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
Y-MABS Therapeutics, Inc. has filed its definitive proxy statement for its annual stockholder meeting on July 11, 2025, where shareholders will vote on the election of a Class I Director, the ratification of its independent auditor, and executive compensation.
Y-mAbs Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on July 11, 2025, to vote on director election, auditor ratification, and executive compensation.
Y-mAbs Therapeutics will hold its annual stockholder meeting on June 11, 2024, to elect directors, ratify the appointment of PricewaterhouseCoopers LLP, and approve executive compensation.
Y-mAbs Therapeutics will hold its 2024 Annual Meeting of Stockholders virtually on June 11, 2024, to vote on director elections, auditor ratification, and executive compensation.